Physician profile
Alla Chernenko
NPI 1972759207
$1,585.81
in general payments reported to CMS, 2019-2025
18 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $78.81 · 2022: $36.43 · 2023: $463 · 2024: $270 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $555.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $168.77 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $144.95 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $92.36 | 2019-2023 | |
| Abbott Laboratories | $74.89 | 2023-2024 | Freestyle Libre 3 |
| Pfizer INC. | $69.22 | 2024-2025 | |
| Abbvie INC. | $68.56 | 2019-2023 | Qulipta, Ubrelvy |
| Amgen INC. | $61.32 | 2025 | Otezla, Repatha |
| Eisai INC. | $52.51 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.58 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.51 | 2019-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $42.29 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $36.76 | 2023-2025 | Trelegy Ellipta |
| Dexcom, INC. | $33.35 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $30.84 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.42 | 2025 | Immunocap |
| Exact Sciences Corporation | $22.41 | 2025 | The Cologuard Plus Collection Kit |
| Medicure Pharma INC. | $13.69 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Chernenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.